Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.40 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 2/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTGIS | Q16647 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25917431 | 0.86 | CYP4F2 (0.43) | RXRARXRBRXRGTBXAS1CYP4F2 | |
| SCHEMBL12272136 | 0.86 | RXRA (0.55) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL25917489 | 0.82 | RXRA (0.40) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30723809 | 0.82 | RXRA (0.46) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL22941287 | 0.82 | RXRA (0.45) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL30724001 | 0.80 | RXRA (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL25918142 | 0.80 | RXRA (0.39) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL1760288 | 0.80 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL20818033 | 0.80 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 | |
| SCHEMBL3868044 | 0.80 | RXRA (0.43) | RXRARXRBRXRGCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024006776-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND MEDICAL USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. (CN) | 2023-08-03 | — | — | US | disclosed |
| EP-4174059-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | Medshine Discovery Inc. (CN) | 2023-05-03 | — | — | EP | disclosed |
| WO-2022001971-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | 南京明德新药研发有限公司 | 2022-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242507-A1 | INDAZOLE-FUSED CYCLIC COMPOUND | SLC5A11, CYP11B2, CYP4F11 | RXRA 3699/4885RXRB 3804/4885RXRG 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.